{"entity":{"id":"nct07621159","kind":"trial","name":"A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer","aka":[],"tldr":"A phase 1/2 trial of HDM2017 and fruquintinib in colorectal cancer, run by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., not yet recruiting.","summary":"A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer is a phase 1/2, interventional study registered as NCT07621159 by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., with a registry enrolment figure of 120 participants, started 2026-07-15 and due to reach its primary completion in 2027-11-01. Interventions recorded: HDM2017; Fruquintinib. Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Maximum Tolerated Dose (MTD); Recommended Phase 2 Dose (RP2D); Type, incidence and severity of Adverse Events. Colorectal eligibility wording from the registry: \"Participants with histologically or cytologically confirmed unresectable locally advanced or metastatic colorectal adenocarcinoma\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07621159","url":"https://clinicaltrials.gov/study/NCT07621159"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["antiangiogenic","kinase-inhibitors"],"targets":[],"drugs":["hdm2017","fruquintinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07621159","phase":"1/2","setting":"A Phase Ib/II Clinical Study to Evaluate the Preliminary Efficacy and Safety of HDM2017 in Combination With Standard of Care in Participants With Advanced Colorectal Cancer","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","enrolled":120,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07621159/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/"},{"id":"hdm2017","kind":"drug","name":"HDM2017","route":"/drugs/hdm2017/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}